Redcare Pharmacy’s Early Guidance Upgrade Ignites a Chart-Breaking Rally
Published on 06/16/2026 at 18:14 | Redaktion boerse-global.de
Redcare Pharmacy blindsided the market on Monday by publishing a mid-year profit warning upgrade nearly a month earlier than the usual July schedule, a move that sent its shares rocketing through the €60 barrier on Tuesday. The stock closed at €61.95, a near-10% jump, after briefly trading around €60.50 earlier in the session. The surge marks a 30% gain over the past week alone.
The decision to move up the guidance refresh reflected a sharp acceleration in April and May. Management now expects full-year revenue growth of 15% to 17%, up from the previous 13%–15% range. The revised forecast for German prescription drugs (Rx) is particularly aggressive: revenues of €680 million to €720 million, implying a maximum uptick of 43%. Meanwhile, the company’s adjusted EBITDA margin is projected to land between 2.5% and 3.0%, a notable improvement from earlier guidance.
The digital prescription business is doing the heavy lifting. E?prescription revenue in Germany jumped 57% in the first two months of the second quarter, propelled by the “Card?Link” system that streamlines access. The broader DACH segment expanded 21% in the same period. Over?the?counter sales are forecast to rise as much as 12% in parallel.
Should investors sell immediately? Or is it worth buying Redcare Pharmacy?
On the charts, Tuesday’s close above the 200?day moving average of €59.43 is the first such breakthrough in more than a year. The stock has more than doubled from its multi?year low of €30.06 set in March, though it still trades 44% below the 52?week peak of €112.10. The relative strength index sits at 77.6, territory that often signals a short?term breather, but the underlying trend is clearly upward.
Analysts have taken notice. Metzler called the early update a powerful signal of momentum. Jefferies maintains its €83 price target with a buy rating, while UBS lifted its target to €60 but keeps a neutral stance. The company’s annualised volatility of nearly 70% underscores the risk, but the directional shift is becoming hard to ignore.
Regulatory tailwinds remain intact. Germany’s pharmacy reform has done little to slow Redcare’s digital push, and the company is rolling out biometric verification for e?prescriptions by the end of 2026 to further simplify the process. All eyes now turn to the half?year report due in late July, when the market will test whether the upgraded outlook holds across the full portfolio, especially in international markets where profitability still needs to prove itself.
Ad
Redcare Pharmacy Stock: New Analysis - 16 June
Fresh Redcare Pharmacy information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
